Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance (Form 8-K)

Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance

•Revenue of $1.375 Billion

•Revenue Grew 7% as Reported and 8% on a Constant Currency1 Basis Compared to the Third Quarter of 2025

•GAAP Net Income Attributable to Bausch + Lomb Corporation of $32 Million

•Adjusted EBITDA (non-GAAP)1 and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $325 Million

•Raising Full-Year 2026 Revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance

VAUGHAN, Ontario, Oct. 28, 2026 - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2026 financial results.

"Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability," said Thomas J. Appio, chairman and interim CEO, Bausch + Lomb. "We have delivered against the commitments outlined at Investor Day for four consecutive quarters, and I believe there are additional opportunities to improve execution, enhance profitability and create even more value over time."

Select Company Highlights

•MIEBO® reported revenue grew 42% to $119 million in the quarter, demonstrating continued momentum in an expanding category

•LUMIFY® reported revenue grew 35%, extending the brand's strong growth trajectory

•Daily SiHy portfolio reported revenue grew 24%, reflecting durable growth across the broader contact lens business

•Premium IOL reported revenue grew approximately 70%, reinforcing the significant growth opportunity in Surgical

•Pipeline positioned to support growth well into the next decade, with several potential first-in-class assets reaching clinical and regulatory milestones in the third quarter

Third-Quarter 2026 Revenue Performance

Total reported revenue was $1.375 billion for the third quarter of 2026, as compared to $1.281 billion in the third quarter of 2025, an increase of $94 million, or 7%. Excluding the unfavorable impact of foreign exchange of $6 million, revenue increased by approximately 8% on a constant currency1 basis compared to the third quarter of 2025.

___________________________________

1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly comparable GAAP measure.

1 | Page

Revenue by segment was as follows:

Third-Quarter 2026

(in millions)						Three Months Ended September 30																								Change at Constant Currency1 (non-GAAP)
						2026						2025						Reported Change						Reported Change
Total Bausch + Lomb Revenue						$1,375						$1,281						$94						7		%				8		%
Vision Care						$774						$736						$38						5		%				6		%
Surgical						$234						$215						$19						9		%				9		%
Pharmaceuticals						$367						$330						$37						11		%				11		%

Vision Care Segment

Vision Care segment revenue was $774 million for the third quarter of 2026, as compared to $736 million for the third quarter of 2025, an increase of $38 million, or 5%. Excluding the unfavorable impact of foreign exchange of $5 million, segment revenue increased on a constant currency1 basis by approximately 6% compared to the third quarter of 2025. Performance was primarily driven by growth from daily SiHy and ULTRA® contact lenses, and LUMIFY® and Artelac® in consumer.

Surgical Segment

Surgical segment revenue was $234 million for the third quarter of 2026, as compared to $215 million for the third quarter of 2025, an increase of $19 million, or 9%. Excluding the unfavorable impact of foreign exchange of $1 million, segment revenue increased on a constant currency1 basis by approximately 9% compared to the third quarter of 2025. Performance was primarily driven by growth in the premium IOL portfolio.

Pharmaceuticals Segment

Pharmaceuticals segment revenue was $367 million for the third quarter of 2026, as compared to $330 million for the third quarter of 2025, an increase of $37 million, or 11% on a reported and constant currency1 basis. Performance was driven by MIEBO growth and increased sales in international pharmaceuticals.

Operating Results

Operating income was $155 million for the third quarter of 2026, as compared to operating income of $95 million for the third quarter of 2025, a favorable change of $60 million. The change was driven by revenue growth noted above and operating efficiencies.

Net Income

Net income attributable to Bausch + Lomb Corporation for the third quarter of 2026 was $32 million, as compared to a $28 million loss for the third quarter of 2025, a favorable change of $60 million. The change was primarily due to operating results noted above.

Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 for the third quarter of 2026 was $123 million, as compared to adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 of $66 million for the third quarter of 2025, an increase of $57 million.

2 | Page

Cash Flow from Operations

Cash flow from operations for the third quarter of 2026 was $233 million, as compared to cash flow from operations of $137 million for the third quarter of 2025, an increase of $96 million. Cash flow from operations was positively impacted by operating results noted above.

Earnings Per Share

GAAP Earnings Per Share ("EPS") Basic and Diluted attributable to Bausch + Lomb Corporation for the third quarter of 2026 was $0.09, as compared to ($0.08) for the third quarter of 2025. Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the third quarter of 2026 was $0.34, as compared to $0.18 for the third quarter of 2025.

Adjusted EBITDA (non-GAAP)1; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

Adjusted EBITDA (non-GAAP)1 was $325 million for the third quarter of 2026, as compared to $243 million for the third quarter of 2025, an increase of $82 million. Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 was $325 million for the third quarter of 2026, as compared to $243 million for the third quarter of 2025, an increase of $82 million. The change was primarily due to revenue growth noted above and operating efficiencies.

3 | Page

2026 Financial Outlook2

Bausch + Lomb provided updated guidance for the full year of 2026 as follows:

As of July 29, 2026

As of Oct. 28, 20263

Full-Year Revenue

• $5.440B - $5.540B

• $5.450B - $5.550B

• 5.8 - 7.7% constant currency growth1

• 6.1 - 8.0% constant currency growth1

Full-Year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

• $1.025B - $1.075B

• $1.090B - $1.140B

Full-Year Revenue Foreign Exchange Tailwinds

• $45M

• $40M

Full-Year Adj. EBITDA Excluding Acquired IPR&D (non-GAAP)1 Foreign Exchange Tailwinds

• Nominal

• Nominal

Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation of forward-looking Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 to GAAP net income (loss) attributable to Bausch + Lomb Corporation or of forward-looking constant currency revenue growth1 to reported revenue growth, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected non-GAAP measure or ratio. These statements represent forward-looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.

________________________________

2 The guidance in this news release is only effective as of the date given, October 28, 2026, and will not be updated or affirmed unless and until the company publicly announces updated or affirmed guidance. Distribution or reference of this news release following October 28, 2026, does not constitute the company reaffirming guidance. See the "Forward-looking Statements" section for further information.

3 The increase in the anticipated full-year revenue is a result of a $15 million increase in the underlying business outlook, based on continued strong business performance in the third quarter of 2026 and anticipated stronger business performance for the remainder of 2026, partially offset by a decrease of $5 million in expected currency tailwinds (such decrease is a result of exchange rates moderating). The increases in anticipated constant currency revenue growth and anticipated full-year adjusted EBITDA (excluding acquired IPR&D) are a result of the aforementioned continued strong business performance in the third quarter of 2026 and anticipated stronger business performance for the remainder of 2026.

4 | Page

Balance Sheet Highlights

•Bausch + Lomb's cash, cash equivalents and restricted cash were $515 million at September 30, 2026

•Basic weighted average shares outstanding for the third quarter of 2026 were 357.6 million, and diluted weighted average shares outstanding for the third quarter of 2026 were 361.5 million

Conference Call Details

Date:			October 28, 2026
Time:			8 a.m. ET
Webcast:			https://www.webcaster5.com/Webcast/Page/2883/53395
Participant Event Dial-in:			+1 (888) 506-0062 (North America) +1 (973) 528-0011 (International)
Participant Access Code:			940423
Replay Dial-in:			+1 (877) 481-4010 (North America) +1 (919) 882-2331 (International)
Replay Passcode:			53395 (replay available until Nov. 11, 2026)

About Bausch + Lomb

Our mission is simple - we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.